I haven't had time to look into it, but somebody told me that, under the CHF deal, we were essentially gonna lose our entire stake in the diagnostics business. Maybe AMBS came to realize that this is a horrendous idea. Blood-based biomarker tests for neurological diseases are the wave of the future. AMBS could be sitting on a goldmine with their diagnostics assets. I think they well may be, and this is starting to come into focus.